Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 24 of 24 entries
View as:

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01208766 Org: User:
Start: 01/31/11 End: 01/31/25 Due: 01/31/26

A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT04139252 Org: User:
Start: 03/17/20 End: 06/30/23 Due: 06/30/24

Study to Assess an Interphase Cycle With Flotetuzumab.

Phase: N/A Priority: Normal
NCT ID: NCT05063123 Org: User:
Start: 01/31/22 End: 12/31/26 Due: 12/31/27

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Phase: N/A Priority: Normal
NCT ID: NCT03356054 Org: User:
Start: 03/05/18 End: 02/28/27 Due: 02/28/28

Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00121303 Org: User:
Start: 01/31/05 End: 06/30/16 Due: 06/30/17

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06220032 Org: User:
Start: 08/15/24 End: 12/15/28 Due: 12/15/29

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

Phase: N/A Priority: Normal
NCT ID: NCT03673826 Org: User:
Start: 11/19/18 End: 12/31/28 Due: 12/31/29

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Phase: N/A Priority: Normal
NCT ID: NCT04097470 Org: User:
Start: 12/05/19 End: 11/30/26 Due: 11/30/27

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Phase: N/A Priority: Normal
NCT ID: NCT03226301 Org: User:
Start: 06/23/17 End: 06/21/26 Due: 06/21/27

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04027309 Org: User:
Start: 12/20/19 End: 06/30/33 Due: 06/30/34

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Phase: N/A Priority: Normal
NCT ID: NCT04639362 Org: User:
Start: 12/29/20 End: 12/01/28 Due: 12/01/29

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Phase: N/A Priority: Normal
NCT ID: NCT04523428 Org: User:
Start: 12/23/20 End: 12/31/32 Due: 12/31/33

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT03463057 Org: User:
Start: 08/30/18 End: 01/31/27 Due: 01/31/28

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

Phase: N/A Priority: Normal
NCT ID: NCT03645824 Org: User:
Start: 06/04/18 End: 02/28/27 Due: 02/28/28

Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission

Phase: N/A Priority: Normal
NCT ID: NCT05502250 Org: User:
Start: 07/14/23 End: 04/30/30 Due: 04/30/31

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

Phase: N/A Priority: Normal
NCT ID: NCT06187441 Org: User:
Start: 05/14/24 End: 12/31/37 Due: 12/31/38

Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.

Phase: N/A Priority: Normal
NCT ID: NCT03541083 Org: User:
Start: 06/04/18 End: 12/15/26 Due: 12/15/27

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

Phase: N/A Priority: Normal
NCT ID: NCT06605586 Org: User:
Start: 02/20/25 End: 03/31/30 Due: 03/31/31

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Phase: N/A Priority: Normal
NCT ID: NCT06652438 Org: User:
Start: 03/31/25 End: 07/10/31 Due: 07/10/32

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

Phase: N/A Priority: Normal
NCT ID: NCT03620578 Org: User:
Start: 08/01/18 End: 10/31/26 Due: 10/31/27

Zanubrutinib in Primary Cold Agglutinin Disease

Phase: N/A Priority: Normal
NCT ID: NCT06067048 Org: User:
Start: 07/26/24 End: 11/01/28 Due: 11/01/29

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

Phase: N/A Priority: Normal
NCT ID: NCT06014489 Org: User:
Start: 01/17/24 End: 03/31/28 Due: 03/31/29

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Phase: N/A Priority: Normal
NCT ID: NCT05791409 Org: User:
Start: 04/10/24 End: 11/30/32 Due: 11/30/33

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03839771 Org: User:
Start: 03/01/19 End: 09/19/34 Due: 09/19/35